Go to Health Care Provider version
| Diagnosis | B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma | Study Status | Open |
| Phase | I/II |
| Age | 6 Months to 25 Years | Randomisation | NO |
| Line of treatment | First line treatment, Disease relapse or progression |
| Routes of Treatment Administration | Biological: Zilovertamab vedotin (IV)
Other Names: MK-2140, VLS-101 |
| Last Posted Update | 2025-08-26 |
| ClinicalTrials.gov # | NCT06395103 |
International Sponsor
Merck Sharp & Dohme LLCPrincipal Investigators for Canadian Sites
Montreal Children's Hospital - Dr. Catherine VézinaCentres
Medical contact
Clinical Research Unit
Social worker/patient navigator contact
Clinical Research Unit
Clinical research contact
Stephanie Badour
Study Description
This study is part of a larger research project. The goal is to see if a new treatment called zilovertamab vedotin is safe and works well for children and young adults whose cancer has come back (relapsed) or did not get better with treatment (refractory).
The study is for patients with B-ALL (a type of leukemia that starts in the bone marrow and blood), DLBCL or Burkitt lymphoma (fast-growing blood cancers that affect the lymph nodes or organs), neuroblastoma (a cancer that starts in nerve cells, usually in young children), or Ewing sarcoma (a cancer of the bones or nearby tissue, often in children and teens).
Inclusion Criteria
- Participant must have one of the following diagnoses:
- Blood cancers: children with a type of leukemia called B-ALL and children with certain fast-growing lymphomas (DLBCL or Burkitt lymphoma) OR
- Solid tumors: children with neuroblastoma or children with Ewing sarcoma
Other inclusion or exclusion criteria may apply and will be discussed with you by the study team.
